Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31;22(17):9469.
doi: 10.3390/ijms22179469.

IGF-1 and IGFBP-3 in Inflammatory Cachexia

Ana Isabel Martín  1 , Teresa Priego  2 , Álvaro Moreno-Ruperez  1 , Daniel González-Hedström  3   4 , Miriam Granado  3   5 , Asunción López-Calderón  1
Affiliations
Review

IGF-1 and IGFBP-3 in Inflammatory Cachexia

Ana Isabel Martín et al. Int J Mol Sci. .

Abstract

Inflammation induces a wide response of the neuroendocrine system, which leads to modifications in all the endocrine axes. The hypothalamic-growth hormone (GH)-insulin-like growth factor-1 (IGF-1) axis is deeply affected by inflammation, its response being characterized by GH resistance and a decrease in circulating levels of IGF-1. The endocrine and metabolic responses to inflammation allow the organism to survive. However, in chronic inflammatory conditions, the inhibition of the hypothalamic-GH-IGF-1 axis contributes to the catabolic process, with skeletal muscle atrophy and cachexia. Here, we review the changes in pituitary GH secretion, IGF-1, and IGF-1 binding protein-3 (IGFBP-3), as well as the mechanism that mediated those responses. The contribution of GH and IGF-1 to muscle wasting during inflammation has also been analyzed.

Keywords: GH; IGF-1; IGFBP-3; cachexia; cytokines; glucocorticoids; inflammation; muscle wasting; nitric oxide; sepsis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Effect of endotoxin or lipopolysaccharide (LPS) administration on the hypothalamic–GH–IGF-1 axis. At low dosage, LPS increased pituitary GH release, but with greater LPS dosages, an increase in hypothalamic somatostatin and a decrease in plasma GH is observed. Endotoxin directly decreased IGF-1 synthesis by hepatocytes through TLR4 activation, inducible nitric oxide synthase (iNOS) induction, and nitric oxide NO release. In addition, Kupffer cells, when stimulated by LPS, release inflammatory mediators (TNF-α, interleukins, and PGS), which further downregulate IGF-1 synthesis in hepatocytes. Whereas most IGF-1 is produced by hepatocytes, IGFBP-3 is mainly synthetized by Kupffer cells [49,50], and its synthesis is decreased by LPS. Red solid arrows indicate stimulatory (+) or inhibitory (−) effects of LPS. Black solid arrows indicate stimulatory and black dotted line indicates inhibitory effects of the hormones implicated in the GH-IGF-1 axis. Red border arrows indicate increased (upward) and decreased (downward) levels of the molecules/mediators in response to LPS.
Figure 2
Figure 2
Role of IGF-1 in inflammation-induced muscle atrophy. The decreased secretion of GH and/or GH resistance, together with the increased release of glucocorticoids (+) induce downregulation of plasma and muscle IGF-1 (−), and the increase in muscle IGFBP-3. Low plasma IGF-1 and high glucocorticoid levels increase atrogenes expression (MuRF-1 and atrogin-1), activate muscle proteolysis by the ubiquitin–proteasome system, and decrease protein synthesis. The increased IGFBP-3 expression together with the low IGF-1 levels in muscles decrease muscle proliferation. Thin arrows indicate stimulatory (+) and dotted ones inhibitory (−) effects of GC (green) and IGF-1 (blue) on muscle. Thick arrows indicate stimulation (green upward arrows) and inhibition (red downward arrows) of molecules/processes in muscle.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Straub R.H. Interaction of the endocrine system with inflammation: A function of energy and volume regulation. Arthritis Res. 2014;16:203. doi: 10.1186/ar4484. - DOI - PMC - PubMed
    1. Soto L., Martin A.I., Millan S., Vara E., Lopez-Calderon A. Effects of endotoxin lipopolysaccharide administration on the somatotropic axis. J. Endocrinol. 1998;159:239–246. doi: 10.1677/joe.0.1590239. - DOI - PubMed
    1. Priego T., Granado M., Ibanez de Caceres I., Martin A.I., Villanua M.A., Lopez-Calderon A. Endotoxin at low doses stimulates pituitary GH whereas it decreases IGF-I and IGF-binding protein-3 in rats. J. Endocrinol. 2003;179:107–117. doi: 10.1677/joe.0.1790107. - DOI - PubMed
    1. Priego T., de Caceres I.I., Martin A.I., Villanua M.A., Lopez-Calderon A. Endotoxin administration increases hypothalamic somatostatin mRNA through nitric oxide release. Regul. Pept. 2005;124:113–118. doi: 10.1016/j.regpep.2004.07.001. - DOI - PubMed
    1. Kasting N.W., Martin J.B. Altered release of growth hormone and thyrotropin induced by endotoxin in the rat. Am. J. Physiol. 1982;243:E332–E337. doi: 10.1152/ajpendo.1982.243.4.E332. - DOI - PubMed

MeSH terms

LinkOut - more resources